These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27788301)

  • 41. Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis.
    Singh S; Singh M; Grewal N; Khosla S
    Am J Ther; 2016; 23(1):e52-62. PubMed ID: 26448337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry.
    Ge Z; Baber U; Claessen BE; Chandrasekhar J; Chandiramani R; Li SX; Sartori S; Kini AS; Rao SV; Weiss S; Henry TD; Kapadia S; Muhlestein B; Strauss C; Toma C; DeFranco A; Effron MB; Keller S; Baker BA; Pocock S; Dangas G; Mehran R
    J Thromb Thrombolysis; 2019 Jul; 48(1):42-51. PubMed ID: 30924052
    [TBL] [Abstract][Full Text] [Related]  

  • 43. One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database.
    Effron MB; Nair KV; Molife C; Keller SY; Page RL; Simeone JC; Murphy B; Nordstrom BL; Zhu Y; McCollam PL; Vetrovec GW
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):129-141. PubMed ID: 29222628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study.
    Chandrasekhar J; Baber U; Sartori S; Faggioni M; Aquino M; Kini A; Weintraub W; Rao S; Kapadia S; Weiss S; Strauss C; Toma C; Muhlestein B; DeFranco A; Effron M; Keller S; Baker B; Pocock S; Henry T; Mehran R
    Catheter Cardiovasc Interv; 2017 Mar; 89(4):629-637. PubMed ID: 27152497
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention.
    Faggioni M; Baber U; Chandrasekhar J; Sartori S; Claessen BE; Rao SV; Vogel B; Effron MB; Poddar K; Farhan S; Kini A; Weintraub W; Toma C; Sorrentino S; Weiss S; Snyder C; Muhlestein JB; Kapadia S; Keller S; Strauss C; Aquino M; Baker B; Defranco A; Pocock S; Henry T; Mehran R
    Int J Cardiol; 2019 Jan; 275():31-35. PubMed ID: 30391067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
    Wilcox R; Iqbal K; Costigan T; Lopez-Sendon J; Ramos Y; Widimsky P
    Curr Med Res Opin; 2014 Nov; 30(11):2193-205. PubMed ID: 25025610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
    Verdoia M; Barbieri L; Suryapranata H; De Luca G
    Platelets; 2016; 27(2):93-104. PubMed ID: 25970631
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study.
    Chandrasekhar J; Baber U; Sartori S; Aquino M; Moalem K; Kini AS; Rao SV; Weintraub W; Henry TD; Vogel B; Ge Z; Muhlestein JB; Weiss S; Strauss C; Toma C; DeFranco A; Claessen BE; Keller S; Baker BA; Effron MB; Pocock S; Dangas G; Kapadia S; Mehran R
    Clin Res Cardiol; 2020 Jun; 109(6):725-734. PubMed ID: 31915997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prasugrel versus clopidogrel in acute coronary syndromes treated with PCI: Effects on clinical outcome according to culprit artery location.
    De Servi S; Goedicke J; Ferlini M; Palmerini T; Syvänne M; Montalescot G
    Int J Cardiol; 2016 Nov; 223():632-638. PubMed ID: 27565841
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
    JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).
    Baber U; Li SX; Pinnelas R; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e006144. PubMed ID: 29870385
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
    Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
    J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical significance of platelet reactivity during prasugrel therapy in patients with acute myocardial infarction.
    Sato T; Namba Y; Kashihara Y; Tanaka M; Fuke S; Yumoto A; Saito H
    J Cardiol; 2017 Jul; 70(1):35-40. PubMed ID: 27836373
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
    Verlinden NJ; Coons JC; Iasella CJ; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):546-551. PubMed ID: 28279076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study.
    Chandrasekhar J; Baber U; Mehran R; Aquino M; Sartori S; Yu J; Kini A; Sharma S; Skurk C; Shlofmitz RA; Witzenbichler B; Dangas G
    J Thromb Thrombolysis; 2016 Aug; 42(2):186-96. PubMed ID: 27100112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk of bleeding and repeated bleeding events in prasugrel-treated patients: a review of data from the Japanese PRASFIT studies.
    Nishikawa M; Isshiki T; Kimura T; Ogawa H; Yokoi H; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    Cardiovasc Interv Ther; 2017 Apr; 32(2):93-105. PubMed ID: 28097639
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program.
    Xie JX; Gunzburger EC; Kaun L; Plomondon ME; Barón AE; Waldo SW; Virani SS; Maddox TM; Mavromatis K
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e005455. PubMed ID: 31665896
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
    De Servi S; Goedicke J; Schirmer A; Widimsky P
    Eur Heart J Acute Cardiovasc Care; 2014 Dec; 3(4):363-72. PubMed ID: 24818952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.